A New Path to Treat Tuberculosis

  • Author: Sarah Maier
  • Published: 21 September 2019
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Nature Communications/Springer Nature Limited
thumbnail image: A New Path to Treat Tuberculosis

Tuberculosis, caused by the bacterium Mycobacterium tuberculosis (Mtb), is a dangerous infectious disease and responsible for ca. 1.8 million fatalities in 2016. Unlike many other pathogenic bacteria that can be cleared from the body quickly through antibiotic treatment, Mtb is able to form a persistent state which is difficult to target. Therefore, current tuberculosis treatment requires a combination therapy using different antibiotics over six months. This prolonged treatment is straining for the affected patient and greatly increases the risk of resistances. Tuberculosis cases caused by multi-resistant bacteria are already a serious health issue.


Michael Berney, Albert Einstein College of Medicine, Bronx, NY, USA, and colleagues have shown that the aspartate pathway, a metabolic pathway which does not exist in humans or animals, is a vulnerable target in the Mtb metabolism. The uptake of the amino acid aspartate from the environment and its metabolism are crucial for the survival of Mtb. Various essential amino acids, such as threonine, are produced via the aspartate pathway, as well as other building blocks such as diaminopimelate, which is necessary for the formation of bacterial cell walls.


The researchers genetically modified Mtb strains in such a way that they were unable to synthesize threonine or its precursor homoserine via the aspartate pathway. Their experiments proved that the modified bacteria strains could not survive without the supplementation of these compounds. Therefore, inhibition of the aspartate pathway could be a promising approach for the discovery of new anti-tuberculosis drugs.


 

Article Views: 1062

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH